Summit Hotel Properties, Inc. (INN) News
Filter INN News Items
INN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INN News Highlights
- INN's 30 day story count now stands at 5.
- Over the past 21 days, the trend for INN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CBD and DRUG are the most mentioned tickers in articles about INN.
Latest INN News From Around the Web
Below are the latest news stories about SUMMIT HOTEL PROPERTIES INC that investors may wish to consider to help them evaluate INN as an investment opportunity.
Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory BoardInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneering pharmaceutical technology company specializing in innovative wellness products, is elated to announce the appointment of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Scientific Advisory Board (SAB). Dr. Pergolizzi, a distinguished expert in the field of pain management and critical care medicine, will be instrumental in the Company's upcoming planned FDA filing for human medications. |
SUMMIT HOTEL PROPERTIES PUBLISHES 2023 CORPORATE RESPONSIBILITY REPORTSummit Hotel Properties, Inc. (NYSE: INN) (the "Company") today announced the publication of its annual Corporate Responsibility Report for 2023, which presents the Company's ongoing commitment to creating long-term value for the business and industry by investing responsibly in safeguarding the environment and supporting its employees, communities, and other stakeholders. |
Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy TestInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its hair care cream (the "Product"). |
Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD InjectionInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the results of a clinical study regarding the pain-relieving effects and safety of the Company's subcutaneous liposomal CBD (Innocan's LPT platform) for dogs with osteoarthritis. Published in the Frontiers in Veterinary Science Journal, under the research topic "Use of Cannabis Derivatives in Veterinary Medicine" (the "Study"). The Study highlights that CBD plasma levels were dete |
Innocan Pharma Reports Q2 2023 Results Including US$2.706M Increase in Revenues Compared to Q2, 2022Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property portfolio, is pleased to announce its financial results for the three and six months period ended June 30, 2023. |
Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief TreatmentInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company specializing in innovative wellness products, today unveiled the successful results of a controlled efficacy trial (the "Trial") of their diabetic foot relief cream (the "Product"). |
Innocan Pharma Announces Closing of Private PlacementInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has today closed a non-brokered private placement offering of 8,409,735 units of Innocan (the "Units") at a price of C$0.23 per Unit for aggregate gross proceeds of C$1,934,239 (the "Offering"). |
Q2 2023 Summit Hotel Properties Inc Earnings CallQ2 2023 Summit Hotel Properties Inc Earnings Call |
Summit Hotel Properties (INN) Reports Q2 Earnings: What Key Metrics Have to SayWhile the top- and bottom-line numbers for Summit Hotel Properties (INN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
Summit Hotel Properties (INN) Q2 FFO and Revenues Top EstimatesSummit Hotel Properties (INN) delivered FFO and revenue surprises of 28.57% and 1.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |